Tamoxifen for relapse of ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 3, 2010, Pages

  Williams, Chris ^a   Simera, Iveta ^b   Bryant, Andrew ^c  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVERSE EVENT; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LABORATORY TEST; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; FEMALE; OVARY TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TAMOXIFEN;

EID: 77951222640     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001034.pub2     Document Type: Review

References (48)

1. Abu-Jawdeh G, Jacobs T, Niloff J, Cannistra S. Oestrogen receptor expression is a common feature of ovarian borderline tumors. Gynecologic Oncology 1996;60:301-7.
2. Ahlgren J, Ellison N, Gottleib R, Laluna F, et al.Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. Journal of Clinical Oncology 1993;11:1957-68.
3. Ahlgren J, Ellison N, Lokich J, Ueno W, et al.High-dose tamoxifen: extended palliation in patients with chemoresistant epithelial ovarian cancer. American Society of Clinical Oncology 1993;12:258(abstr 817).
4. Anderl P, Fuith L, Daxenbichler G, Marth C, Dapunt O. Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. Gynecology and Obstetrics Investigations 1988;25:135-40.
5. Beecham J, Blessing, Creasman W, Hatch K. Tamoxifen responsiveness, hormone receptors, and tumor grade: a prospective study. Gynecologic Oncology 1988;29:136 (abstr 24).
6. Belinson J, McClure M, Badger G. Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecologic Oncology 1987;28:151-5.
7. Bruzzone M, Catsafados E, Miglietta L, Amoroso D, et al.Tamoxifen and LH-RH analogues in platinum refractory advanced ovarian cancer patients: a palliative treatment with favourable cost-benefit balance. Tumori 1995;81:65 (abstr 180).
8. Gennatas C, Dardoufas C, Karvouni H, Kairi E, Zourlas P. Phase II trial of tamoxifen in patients with advanced epithelial ovarian cancer. American Society of Clinical Oncology 1996;15(abstr782):287.
9. Hamerlynck J, Vermorken J, Van Der Berg M, Ten Bokkel Huinink W, Van Oostrom A, Carnino F, De Olivera C, Rotmensz N. Phase II study of tamoxifen in advanced ovarian cancer. Third European Conference on Clinical Oncology Cancer Nursing (ECCO 3);1985 June 16-20; Stockholm. 1985:117.
10. Hamerlynck J, Vermorken J, Van Der Berg M, Ten Boekkel Huinink W, et al.Tamoxifen therapy in advanced ovarian cancer: a phase II study. American Society of Clinical Oncology 1985;4:115 (abstr C-447).
11. Harvey V, Osborne R, Slevin M. A phase II study of tamoxifen in recurrent ovarian carcinoma. Medical and Pediatric Oncology 1987;15:147 (abstr 122).
12. Hatch K, Beecham J, Blessing J, Creasman W. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68:269-71.
13. Holt JA, Caputo TA, Kelly KM, Greenwald P, Chorost S. Estrogen and progesterone binding in cytosis of ovarian adenocarcinomas. Obstetrics and Gynaecology 1979;53:50-8.
14. Jaeger W. A randomized comparison of decapeptyl and tamoxifen as treatment of progressive ovarian cancer. Gynecological Endocrinology 1993;7 Suppl 2:70 (abstr 123).
15. Jager W, Sauerbrei W, Beck E, Massen V, et al.A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Research 1995;15:2639-42.
16. Jakobsen A, Bertelsen K, Sell A. Cyclical hormonal treatment in ovarian cancer. A phase-II trial. European Journal of Cancer and Clinical Oncology 1987;23:915-16.
17. Landoni F, Ghelardoni C, Zanini A, Colombo N. Tamoxifen in advanced epithelial ovarian cancer. Journal of Steroid Biochemistry 1983;19 Suppl 93S:abstr 278.
18. Landoni F, Regallo M, Vassena L, Bonazzi C, et al.Antiestrogen as last-line treatment in epithelial ovarian cancer (tamoxifen). Chemioterapia. 1985; Vol. 4 Suppl to No 2.
19. Lopez A, Tessadrelli A, Kudelka A, Edwards, et al.Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer. International Journal of Gynecological Oncology 1996;6:15-9.
20. Losa G, Landoni F, Pellegrino A, Parma G, Miceli D, Maneo A, Marzola M. Treatment of advanced ovarian cancer by hormone. International Journal of Gynecological Cancer 1993;3(Suppl 1):66.
21. Markman M, Iseminger K, Hatch K, Creasman W, et al.Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecologic Oncology 1996;62:4-6.
22. Marth C, Sorheim N, Kaern J, Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma. International Journal of Gynecological Cancer 1997;7:256-61.
23. Milward M, Lien E, Robinson A, Cantwell B. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 1994;51:79-83.
24. Millward M, Cantwell B, Lien E, Carmichael J, Harris A. Intermittent high-dose tamoxifen as a potential modifer of multidrug resistance. European Journal of Cancer 1992;Part A 28A:805-10.
25. Osborne R, Slevin M, Harvey V, Shepherd, et al.Tamoxifen loading dose schedule in refractory ovarian cancer. American Society of Clinical Oncology 1987;6:121 (abstr 477).
26. Osborne R, Slevin M, Harvey V, Shepherd J, et al.Tamoxifen in a loading dose schedule in refractory ovarian cancer. British Journal of Cancer 1987;56:218-9.
27. Osborne R, Malik S, Slevin V, Harvey V, et al.Tamoxifen in refractory ovarian carcinoma: the use of a loading dose schedule. British Journal of Cancer 1988;57:115-6.
28. Schwartz P, Chambers J, Kohrn E, Chambers S, et al.Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989;63:1074-8.
29. Schwartz P, Keating G, Maclusky N, Eienfeld A. Tamoxifen therapy for advanced ovarian cancer. American Association Cancer Research American Society of Clinical Oncology 1980;21:430 (abstr C443).
30. Shirey D, Kavanagh J, Gershenson D, Freedman R, et al.Tamoxifen therapy of epithelial ovarian cancer. Obstetrics and Gyneacology 1985;66:575-78.
31. Slevin M, Harvey V, Osborne R, Shepherd J, et al.A phase II study of tamoxifen in ovarian cancer. European Journal of Cancer and Clinical Oncology 1986;22:309-12.
32. Trippa F, Buzzi F, Acito L, Torresi U, Contu A. Combination of tamoxifen and N-interferon beta in patients with progressive ovarian carcinoma. Tumori 1993;79(3):68 (abstr 205).
33. Van Der Vange N, Greggi S, Burger C, KenemansP, Vermorken J. Experience with hormonal therapy in advanced ovarian cancer. Acta Oncologica 1995;34:813-20.
34. van der Velden J, Gitsch G, Wain G, Friedlander M, Hacker N. Tamoxifen in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer 1995;5:301-5.
35. Weiner S, Alberts D, Surwit E, Davis J, et al.Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecologic Oncology 1987;27:208-213.
36. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303:884-93.
37. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The Results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;Vol. 50(No. 6):683-91.
38. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook [updated June 2000]. In: The Cochrane Library [database on CD ROM]. The Cochrane Collaboration. Oxford: Update Software; 2002, Issue 1.
39. CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
40. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
42. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
43. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
44. Gronroos M, Kangas L, Nieminen A, Maenpaa J. Correlation of steroid receptor contents with tamoxifen and medroxyprogesterone effects in ovarian cancer cell assayed by in-vitro ATP bioluminescence method. Journal of Steroid Biochemistry 1983;19 Suppl 72S:(abstr 217).
45. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
46. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
47. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
48. Williams CJ. Tamoxifen in relapsed ovarian cancer: A systematic review. International Journal of Gynecological Cancer 1988;8:89-94.